Patents by Inventor NICOLAS MASURIER

NICOLAS MASURIER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and compositions for the treatment of neurodegenerative and inflammatory diseases
    Patent number: 11541023
    Abstract: The invention relates to compounds exhibiting kallikrein inhibitory activity, and to compositions comprising at least one of these compounds for use in the treatment of diseases or disorders in which kallikrein activity is dysregulated, particularly neurodegenerative and inflammatory diseases.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: January 3, 2023
    Assignees: SARBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS, INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE, UNIVERSITÉ DE MONTPELLIER, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER
    Inventors: Chahrazade El Amri, Feryel Soualmia, Nicolas Masurier, Sabrina Aït Amiri, Brahim Nait Oumesmar, Cyrille Deboux
  • MODIFIED PEPTIDES AND THEIR USE
    Publication number: 20220242905
    Abstract: The invention relates to a compound of formula (A) wherein n is an integer from 1 to 6, and R1, R1?, R2, R2?, R3, R3? are cationic or hydrophobic residues.
    Type: Application
    Filed: September 26, 2019
    Publication date: August 4, 2022
    Inventors: Clément BONNEL, Baptiste LEGRAND, Ludovic MAILLARD, Nicolas MASURIER, Jean MARTINEZ, Patricia LICZNAR-FAJARDO, Estelle JUMAS-BILAK
  • COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES
    Publication number: 20210046026
    Abstract: The invention relates to compounds exhibiting kallikrein inhibitory activity, and to compositions comprising at least one of these compounds for use in the treatment of diseases or disorders in which kallikrein activity is dysregulated, particularly neurodegenerative and inflammatory diseases.
    Type: Application
    Filed: February 13, 2019
    Publication date: February 18, 2021
    Inventors: CHAHRAZADE EL AMRI, FERYEL SOUALMIA, NICOLAS MASURIER, SABRINA AÏT AMIRI, BRAHIM NAIT OUMESMAR, CYRILLE DEBOUX